3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:百万円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 39,947 | 40,885 |
受取手形、売掛金及び契約資産 | ※1 47,425 | ※1 46,619 |
リース投資資産 | 188 | 209 |
商品及び製品 | 6,093 | 5,580 |
仕掛品 | 7,929 | 8,509 |
原材料及び貯蔵品 | 8,439 | 7,183 |
その他 | 13,875 | 11,018 |
貸倒引当金 | △678 | △863 |
流動資産合計 | 123,220 | 119,143 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物 | ※2 58,092 | ※2 56,543 |
減価償却累計額 | △29,650 | △30,297 |
建物及び構築物(純額) | 28,441 | 26,246 |
機械装置及び運搬具 | ※2 29,868 | ※2 23,636 |
減価償却累計額 | △16,530 | △16,534 |
機械装置及び運搬具(純額) | 13,338 | 7,101 |
工具、器具及び備品 | ※2 46,813 | ※2 44,382 |
減価償却累計額 | △29,965 | △30,404 |
工具、器具及び備品(純額) | 16,847 | 13,977 |
土地 | 10,129 | 9,700 |
リース資産 | 21,491 | 28,206 |
減価償却累計額 | △11,026 | △12,836 |
リース資産(純額) | 10,465 | 15,370 |
建設仮勘定 | 2,179 | 1,152 |
有形固定資産合計 | 81,400 | 73,549 |
無形固定資産 | | |
のれん | 7,399 | 7,682 |
顧客関連無形資産 | 1,968 | 1,724 |
ソフトウエア | ※2 17,825 | ※2 17,304 |
リース資産 | 316 | 196 |
ソフトウエア仮勘定 | 10,401 | 9,953 |
その他 | 7,920 | 7,422 |
無形固定資産合計 | 45,832 | 44,283 |
投資その他の資産 | | |
投資有価証券 | ※3 6,438 | ※3 1,801 |
長期貸付金 | 52 | 4,860 |
差入保証金 | 18,065 | 17,835 |
繰延税金資産 | 10,450 | 13,881 |
その他 | ※3 5,701 | ※3 4,157 |
貸倒引当金 | △411 | △2 |
投資その他の資産合計 | 40,297 | 42,534 |
固定資産合計 | 167,530 | 160,367 |
繰延資産 | | |
社債発行費 | 99 | 70 |
繰延資産合計 | 99 | 70 |
資産合計 | 290,849 | 279,582 |
| | (単位:百万円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
負債の部 | | |
流動負債 | | |
支払手形及び買掛金 | 19,729 | 18,908 |
電子記録債務 | 1,091 | 301 |
短期借入金 | - | 10,000 |
1年内償還予定の社債 | 10,000 | - |
1年内返済予定の長期借入金 | - | 10,045 |
リース債務 | 3,849 | 4,470 |
未払金 | 16,027 | 9,876 |
未払法人税等 | 785 | 1,232 |
賞与引当金 | 6,109 | 6,266 |
その他 | ※4 6,475 | ※4 8,337 |
流動負債合計 | 64,070 | 69,438 |
固定負債 | | |
社債 | 31,100 | 31,100 |
長期借入金 | 29,000 | 19,182 |
リース債務 | 7,996 | 11,855 |
退職給付に係る負債 | 7,174 | 6,935 |
資産除去債務 | 1,571 | 1,561 |
株式給付引当金 | 75 | 277 |
補償損失引当金 | 637 | 279 |
債務保証損失引当金 | 699 | - |
その他 | 6,020 | 1,657 |
固定負債合計 | 84,274 | 72,848 |
負債合計 | 148,344 | 142,287 |
純資産の部 | | |
株主資本 | | |
資本金 | 9,279 | 9,279 |
資本剰余金 | 25,001 | 25,094 |
利益剰余金 | 97,700 | 93,309 |
自己株式 | △2,256 | △2,258 |
株主資本合計 | 129,724 | 125,425 |
その他の包括利益累計額 | | |
その他有価証券評価差額金 | 1,498 | △9 |
為替換算調整勘定 | 13,209 | 12,942 |
退職給付に係る調整累計額 | △2,014 | △1,347 |
その他の包括利益累計額合計 | 12,692 | 11,586 |
新株予約権 | 88 | 102 |
非支配株主持分 | - | 180 |
純資産合計 | 142,505 | 137,295 |
負債純資産合計 | 290,849 | 279,582 |
E0096745440H.U.グループホールディングス株式会社H.U. Group Holdings, Inc.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse454402023-04-012024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember454402023-04-012024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember454402023-04-012024-03-31jppfs_cor:SubscriptionRightsToSharesMember454402024-03-31jppfs_cor:CapitalStockMember454402024-03-31jppfs_cor:CapitalSurplusMember454402024-03-31jppfs_cor:RetainedEarningsMember454402024-03-31jppfs_cor:TreasuryStockMember454402024-03-31jppfs_cor:ShareholdersEquityMember454402024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember454402024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember454402024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember454402024-03-31jppfs_cor:SubscriptionRightsToSharesMember454402023-03-31jppfs_cor:RetainedEarningsMember454402023-03-31jppfs_cor:TreasuryStockMember454402023-03-31jppfs_cor:ShareholdersEquityMember454402023-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember454402023-04-012024-03-31jppfs_cor:RetainedEarningsMember454402023-04-012024-03-31jppfs_cor:CapitalStockMember454402023-04-012024-03-31jppfs_cor:CapitalSurplusMember454402023-04-012024-03-31jppfs_cor:TreasuryStockMember454402023-04-012024-03-31jppfs_cor:ShareholdersEquityMember454402023-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember454402023-04-012024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember454402025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember454402023-03-31jppfs_cor:SubscriptionRightsToSharesMember454402023-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember454402023-03-31jppfs_cor:CapitalStockMember454402023-03-31jppfs_cor:CapitalSurplusMember454402025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember454402024-04-012025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember454402024-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember454402023-04-012024-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember454402023-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember454402025-03-31jppfs_cor:ShareholdersEquityMember454402025-03-31jppfs_cor:CapitalStockMember454402025-03-31jppfs_cor:CapitalSurplusMember454402025-03-31jppfs_cor:RetainedEarningsMember454402025-03-31jppfs_cor:TreasuryStockMember454402025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember454402025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember454402025-03-31jppfs_cor:SubscriptionRightsToSharesMember454402024-04-012025-03-31jppfs_cor:ShareholdersEquityMember454402024-04-012025-03-31jppfs_cor:CapitalStockMember454402024-04-012025-03-31jppfs_cor:CapitalSurplusMember454402024-04-012025-03-31jppfs_cor:RetainedEarningsMember454402024-04-012025-03-31jppfs_cor:TreasuryStockMember454402024-04-012025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember454402024-04-012025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember454402024-04-012025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember454402024-04-012025-03-31jppfs_cor:SubscriptionRightsToSharesMember454402023-03-31454402024-04-012025-03-31454402025-05-15454402025-03-31454402024-03-31454402023-04-012024-03-31454402024-04-012025-03-31jppfs_cor:NonControllingInterestsMember454402025-03-31jppfs_cor:NonControllingInterestsMember454402024-03-31jppfs_cor:NonControllingInterestsMember454402024-04-012025-03-31tse-acedjpfr-45440:InVitroDiagnosticsBusinessReportableSegmentsMember454402024-04-012025-03-31tse-acedjpfr-45440:SterilizationAndRelatedServicesReportableSegmentsMember454402024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember454402025-03-31tse-acedjpfr-45440:ClinicalLabTestingBusinessReportableSegmentsMember454402025-03-31tse-acedjpfr-45440:InVitroDiagnosticsBusinessReportableSegmentsMember454402025-03-31tse-acedjpfr-45440:SterilizationAndRelatedServicesReportableSegmentsMember454402025-03-31jpcrp_cor:ReconcilingItemsMember454402024-03-31tse-acedjpfr-45440:ClinicalLabTestingBusinessReportableSegmentsMember454402024-03-31tse-acedjpfr-45440:InVitroDiagnosticsBusinessReportableSegmentsMember454402024-03-31tse-acedjpfr-45440:SterilizationAndRelatedServicesReportableSegmentsMember454402024-03-31jpcrp_cor:ReconcilingItemsMember454402023-04-012024-03-31tse-acedjpfr-45440:ClinicalLabTestingBusinessReportableSegmentsMember454402023-04-012024-03-31tse-acedjpfr-45440:InVitroDiagnosticsBusinessReportableSegmentsMember454402023-04-012024-03-31tse-acedjpfr-45440:SterilizationAndRelatedServicesReportableSegmentsMember454402023-04-012024-03-31jpcrp_cor:ReconcilingItemsMember454402024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember454402024-04-012025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember454402025-03-31jpcrp_cor:ReportableSegmentsMember454402025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember454402024-03-31jpcrp_cor:ReportableSegmentsMember454402024-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember454402023-04-012024-03-31jpcrp_cor:ReportableSegmentsMember454402023-04-012024-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember454402024-04-012025-03-31tse-acedjpfr-45440:ClinicalLabTestingBusinessReportableSegmentsMemberiso4217:JPYxbrli:pure